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Abstract. trans-Resveratrol (trans-3,5,4'-trihydroxystilbene) is a 
natural polyphenol that occurs in grapes, berries, peanuts, and 
several traditional medicines. A number of studies have 
demonstrated that this polyphenol holds promise against numerous 
age-associated diseases including cancer, diabetes, Alzheimer, 
cardiovascular and pulmonary diseases. In view of these studies, 
resveratrol's prospects for use in the clinics are rapidly accelerating. 
This review summarizes our work on the mechanisms involved in 
the intestinal absorption and its population pharmacokinetics. 
Finally, various targets of resveratrol and its therapeutic potential 
are described.  
 
Introduction 
 
 trans-Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenolic compound 
naturally occurring in plants and found in dietary products. Along the past  
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decade our research was devoted to study in depth the mechanism involved in 
its intestinal absorption as the first step to explain the bioavailability of this 
compound. The present review also discusses the processes implicated on its 
distribution and elimination as well as its beneficial effects in colon cancer 
and spermatogenesis. 
 
1. Chemistry of trans-resveratrol 
 
 trans-Resveratrol (3,5,4’-trihydroxistilbene, Fig. 1) is a polyphenol that 
belongs to the stilbene family which is characterized by an essential structural 
skeleton of two aromatic rings joined by an ethylene bridge.  
 
 
  
Figure 1. Chemical structure of trans-resveratrol. 
 
 trans-Resveratrol is formed via a condensation reaction between three 
molecules of malonyl-CoA and one molecule of 4-coumaroyl CoA catalyzed 
by trans-resveratrol synthase. The synthesis of trans-resveratrol in plants is 
triggered in response to exogenous stress factors, such as injury, ultraviolet 
radiation and fungal infection. For this reason, this secondary metabolite of 
plants is defined as a phytoalexin [1]. The concentration of trans-resveratrol 
peaks approximately 42-72 h after stress exposure, and declines after 42-72 h 
as a result of activation of stilbene oxidase [1].  
 This polyphenol exists in both cis- and trans-isomeric forms, the trans-
isomer being the most commonly found and extensively studied. In plants, 
trans-resveratrol is also found as 3-Ο-β-D-glucosides, a compound also known 
as piceid or polydatin, which is more stable and less susceptible to oxidative 
degradation than the parent compound. Other analogs of trans-resveratrol such 
as pterostilbene (3,5-trimethoxy-4’-hydroxystibene) or piceatannol (3,4,3’,5’-
trans-tetrahydroxystilbene) have also been reported in plants [1].  
 
2. Sources of trans-resveratrol 
 
 trans-Resveratrol was first isolated in 1940 as a component of the roots of 
the white hellebore (Veratrum grandiflorum). The term resveratrol comes 
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from this plant, being “res” a latin prefix that means “which comes from” and 
“ol” a suffix indicating the presence of an alcohol moiety in its structure. In 
1963, it was identified as an active constituent of the dried roots of Polygonum 
cuspidatum (0.524 mg/g), also called kojo-kon and used in traditional Asian 
medicine against suppurative dermatitis, gonorrhea and hyperlipemia [2]. In 
Vitis vinifera it was detected in 1976 where this polyphenol is exclusively 
synthesized in leaf epidermis and in grape skins, but not in the flesh [3], and 
in wine in 1992 [4]. Afterward this polyphenol has been described in more 
than 70 plant species [5]. 
 
Table 1. Content of trans-resveratrol in dietary sources. 
 
Source trans-Resveratrol concentration 
Red wine 0.1 – 14.3 mg/L 
White wines 0.1 – 2.1 mg/L 
Grapes 50 – 100 µg/g 
Peanuts 0.02 – 1.92 µg/g 
Pistachios 0.09 – 1.67 µg/g 
Blueberries        ~ 32 ng/g 
Bilberries        ~ 16 ng/g 
 
 In grapes the concentrations of trans-resveratrol ranged from 50 to 100 µg/g 
fresh weight. During mashing, in the winemaking process, part of trans-
resveratrol present in the skin is dissolved in the must. Thus, the concentrations 
of this polyphenol are higher in red wines since the contact between berry skin 
and must is more prolonged, than in white wines, where the must is immediately 
separated from the grape residues. Content of trans-resveratrol in red wine 
ranges from non-detectable concentrations to 14.3 mg/L (62.7 µM). The average 
concentrations of trans-piceid in a red wine could be as much as 29.2 mg/L 
(128.1 µM), i.e., three times that of trans-resveratrol [6]. 
 In addition to grapes and wine (Table 1), trans-resveratrol is found in 
several edible natural products such as peanuts (Arachis hypogaea), berries 
(blueberries, cranberries, blueberries, bilberries, from the Vaccinium family), 
rhubarb (Rheum rhabarbarum), pistachio (Pistacia vera) and hop (Humulus 
lupulus) [1,5]. 
 The occurrence of trans-resveratrol has also been documented in a 
number of trees, such as eucalyptus and spruce, as well as the tropical 
deciduous tree Bauhinia racemosa. It has also been found in a few flowering 
plants [1].  
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3. Intestinal absorption of trans-resveratrol 
 
 The processes that take place in the intestine during the absorption of 
trans-resveratrol have been studied in vivo in rats using a perfusion method 
[7]. A nutritionally relevant concentration of 25 µmol/L of trans-resveratrol 
was used to evaluate the absorption across the jejunum as a function of time. 
Nearly 72% of the luminally perfused polyphenol disappeared from the buffer 
after 30 min, indicating that there was an efficient uptake of this polyphenol. 
At the same time, the result showed that trans-resveratrol was efficiently 
conjugated inside the enterocyte with glucuronic acid by UDP-
glucuronosyltransferase or with sulfate by sulfotransferase, and 42% and 12%, 
respectively, were subsequently pumped back to the luminal side.  
 The kinetic study of trans-resveratrol was performed in jejunal and ileal 
loops perfused with increasing concentrations of this compound. The transport 
rates of the unconjugated polyphenol were directly proportional to the initially 
applied trans-resveratrol, indicating that the uptake occurs by simple 
diffusion, without the participation of a mediated transport, as indicated with 
perfusion using 2,4-dinitrophenol. The apparent diffusion constant (Kd) 
normalized to segment dry weight was 8.1 ± 0.3 μL/5 min·mg dry weight in 
the jejunum and 10.7 ± 0.2 μL/5 min·mg dry weight in the ileum [7]. These 
results are in accordance with findings for Caco-2 cells, where this compound 
crosses the cells by passive diffusion [8]. 
 The efflux of the intracellulary formed trans-resveratrol glucuronide and 
sulfate towards the intestinal lumen was higher in the jejunum than in the 
ileum, indicating a region-dependent metabolism of trans-resveratrol in the 
small intestine according to the regional distribution of UDP-
glucuronosyltransferase and sulfotransferase in the intestine [9]. In both 
segments, the kinetic analysis of trans-resveratrol transformation indicated 
that in the enterocyte, glucuronidation was favored over sulfation, with similar 
rates of reaction. Glucuronidation seems to be the predominant conjugation 
pathway in the rat, and trans-resveratrol glucuronide was excreted form the 
enterocyte to the intestinal lumen with an average concentration 4.5 times 
higher than that of the sulfate [7].  
 The secretion of the conjugates out of the enterocyte was thought to be 
mediated through the ATP-binding cassette (ABC) transporters which are 
efflux proteins that act as “gatekeepers” in the intestine thus controlling the 
oral availability of many substances [10]. This ABC superfamily contains 
membrane proteins that translocate a wide variety of substrates across extra- 
and intracellular membranes, including metabolic products, lipids, sterols, and 
drugs. Of the numerous members of the ABC transporter family, three have 
been described in the apical membrane of the enterocyte: the P-glycoprotein 
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(Pgp; ABCB1), the multidrug resistance-associated protein (MRP2; ABCC2), 
and the breast cancer resistance protein (BCRP; ABCG2) [10,11]. Pgp 
recognizes a wide range of structurally and pharmacologically unrelated 
neutral and positively charged hydrophobic compounds [10]. MRP2 has a 
relatively hydrophobic substrate spectrum, including glucuronide, glutathione 
and sulfate conjugates of endogenous and exogenous [12]. BCRP is the most 
recently discovered of these efflux transporters and recognizes mainly 
hydrophilic anticancer agents as well as negatively charged drug 
conjugates[13].  
 The role of intestinal ABC transporters in the absorption of trans-
resveratrol was investigated with the use of specific inhibitors (Fig. 2). 
Consequently, P-glycoprotein was evaluated by using verapamil and 
cyclosporine [10]. These inhibitors ruled out the possibility that either trans-
resveratrol or its conjugates constituted a substrate of this protein. Intestinal 
perfusions of trans-resveratrol with the MRP2 inhibitors probenecid [14] and 
MK571 [15] did not exhibit any effect on trans-resveratrol. However, 
secretion of glucuronide and sulfate conjugates decreased, thus implicating 
MRP2 in their efflux. These results are in agreement with findings for isolated 
perfused livers, which have indicated that MRP2 exclusively mediates the 
biliary excretion of resveratrol glucuronides and only partly mediates that of 
sulfates [16]. The role of BCRP was analyzed in the presence of Ko143, a 
high affinity and specific BCRP inhibitor [17]. Perfusions with Ko143 
significantly decreased the secretion of trans-resveratrol glucuronide and 
sulfate conjugates without affecting the absorption of the parent compound. 
The role of BCRP was confirmed with the use of BCRP1-/- mice that were 
orally administered with 60 mg/kg of trans-resveratrol [18]. trans-Resveratrol 
and its metabolites were measured in intestinal content at 30 min after 
administration and showed a decrease of 71% and 97% of resveratrol 
glucuronide and sulfate respectively, compared to the wild-type mice, thus 
indicating a lower efflux from the enterocytes [18]. 
 trans-Resveratrol conversion to a mono-glucuronide and a mono-sulfate 
was the only observed transformation in rat intestine under our experimental 
conditions with no cytochrome P450-mediated phase I metabolic 
transformation or methylation [7]. The latter possibility did not take place due 
to the lack of catechol function in the trans-resveratrol molecule, which is a 
requirement for catechol-Ο-methyltransferase (COMT). In addition to the 
conjugates, another metabolite of trans-resveratrol has been described in the 
intestine [19]. This polyphenol is quantitatively transformed into 
dihydroresveratrol, which is a metabolite that may be produced by the 
intestinal microflora since its formation involves the hydrogenation of the 
aliphatic double bond of the parent compound. Dihydroresveratrol was found  
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Figure 2. Effects of inhibitors of Pgp (verapamil, cyclosporine), MRP2 (probenecid, 
MK571) and BCRP (Ko143) on the absorption of trans-resveratrol and the secretion of 
intracellulary formed glucuronide and sulfate conjugates. Results are expressed as 
percentage of trans-resveratrol absorbed or glucuronide and sulfate secreted in the 
absence (100%) or presence of the inhibitor under study. Values are expressed as 
means + SE (n = 4-6). * P < 0.05, significantly different from perfusion with trans-
resveratrol alone; **P < 0.001. 
 
to be the most abundant metabolite in the colon after the oral administration of 
60 mg/kg of trans-resveratrol for 49 days, and 24 hours after the last 
administration, with concentrations of 303.0 ± 34.7 nmol/g, 446-fold that of 
the parent compound [19].  
 
4. Population pharmacokinetics of trans-resveratrol 
  
 The bioavailability and metabolism of trans-resveratrol have been widely 
studied in rats and humans given that its efficacy depends on its absorption 
and metabolism [20]. However, it is difficult to provide an adequate 
pharmacokinetic description of the intricate processes that determine the 
bioavailability of this polyphenol. A preliminary evaluation of the plasmatic 
pharmacokinetics of trans-resveratrol was carried out after the oral 
administration of 2 mg/kg to overnight fasted rats [21]. Blood samples were 
extracted at different time points over an hour, and showed low plasmatic 
concentrations of unchanged trans-resveratrol with peak concentration of 550 
ng/mL at 10 minutes [21]. The low bioavailability for trans-resveratrol 
indicates that the small intestine comes out as the first bottleneck to the entry 
of this compound to the organism [18,21]. In addition, the metabolism in the 
liver cannot be underestimated [22,23] before the distribution to tissues where 
ABC proteins are also present, given that all these processes influence the 
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distribution and subsequent elimination from the organism [18]. As a result of 
this complex interplay between enzyme activities and efflux transporters, the 
concentrations of trans-resveratrol in plasma have been reported to be low 
[20,21]. 
 Given the important metabolism observed for trans-resveratrol, an 
integrated pharmacokinetic model that could describe the parameters of both 
the parent compound and its conjugated metabolites was investigated after 
i.v. and p.o. administration of 2, 10 and 20 mg/kg of trans-resveratrol in 
Sprague-Dawley rats [24]. Analyses of the plasmatic data through the 
population pharmacokinetic approach provided important advantages such 
as overcoming the limitations of blood sampling in studies using 
experimental animals, and at the same time preserving animal individuality. 
In addition, the population approach allows the estimation of the typical 
pharmacokinetic parameters as well as the inter-animal variability. To this 
end, all the data (from parent compound and conjugates) obtained after the 
i.v. administrations of three doses of trans-resveratrol were simultaneously 
analyzed. Once the best intravenous model was found, the disposition 
parameters were fixed and the oral data of the three compounds were added 
to estimate the absorption parameters (absorption rate constants and 
bioavailability). 
 
 
 
Figure 3. Schematic representation of the pharmacokinetic model to simultaneously 
describe the data of trans-resveratrol and its glucuronide and sulfate conjugates after 
i.v. and p.o. administration. 
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 The pharmacokinetics of trans-resveratrol and its conjugates that best 
described our results was a three-linked two compartment model (Fig. 3). 
Elimination of trans-resveratrol by conversion to its glucuronide and sulfate 
took place by a first-order kinetic process. It is noteworthy that the 
transformation of the parent compound to its conjugates was not saturable 
even at the plasmatic concentrations achieved after the highest dose assayed 
(20 mg·kg-1). Meanwhile, clearance of trans-resveratrol glucuronide and 
sulfate was best described by parallel first-order and Michaelis-Menten 
kinetics. These results are in agreement with existing knowledge about 
elimination mechanisms of glucuronide and sulfate in tubular cells and 
hepatocytes [18,25]. The total clearance value of trans-resveratrol was slightly 
higher than ¾ times the hepatic blood flow in the rat (0.90 L/h for a body 
weight of 0.25 kg). According to the fm value obtained (0.540) approximately 
the same percentage of both metabolites was formed. Clearances of formation 
of the glucuronide and sulfate were 0.67 and 0.57 L·h-1, respectively. 
Distribution volume of trans-resveratrol (total distribution volume = 3.05 L) 
exceeded the total body water in the rat (0.15 L·kg-1 for a body weight of 0.25 kg) 
suggesting extensive distribution into tissues. A short half-life value was 
estimated for trans-resveratrol (0.55 h) that was in agreement with its 
clearance and distribution volumes values. By contrast smaller distribution 
volumes were found for the metabolites (total distribution volumes = 0.38 and 
0.14 L for the glucuronide and sulfate, respectively).  
 In order to model the oral data, a depot compartment (intestinal 
compartment) was added to the intravenous model where trans-resveratrol 
was administered. When going into the gastrointestinal tract, trans-resveratrol 
was supposed to be subject to first-pass metabolism and to reach the systemic 
circulation intact or as its glucuronide according to a simple diffusion process. 
The rate limiting step is most likely the absorption process of trans-resveratrol 
and its glucuronide rather than the metabolism. The first-order absorption rate 
constants (Ka1 = 0.442 h-1, absorption half life = 1.57 h, Ka2 = 0.256 h-1, 
absorption/metabolism half life = 2.71 h) confirmed rapid 
absorption/metabolism kinetics for both compounds. The data did not support 
the inclusion of first-pass metabolism of trans-resveratrol to sulfate, so the 
model was simplified to absorption/presystemic metabolism of trans-
resveratrol to its glucuronide and absorption of the formed glucuronide. The 
inclusion of a fraction of the parent compound never absorbed, due to 
metabolism to the conjugates and efflux of them back into intestine, did not 
improve the fit. One of the reasons why trans-resveratrol sulfate could not be 
included in the presystemic metabolism of trans-resveratrol might be the low 
concentrations of this metabolite that reached the bloodstream. These low 
concentrations could be attributed to a lower sulfation compared to the 
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glucuronidation of trans-resveratrol in the rat intestine [26,27]. Moreover, the 
higher affinity and capacity of BCRP for trans-resveratrol sulfate compared to 
the one observed for the glucuronide could account for a higher efficiency in 
the secretion of the sulfate [25]. Andlauer et al. [26] appointed that only 0.3% 
of the absorbed resveratrol reaches the blood as sulfate. Altogether, these 
processes could explain why the model did not support the inclusion of 
presystemic metabolism of trans-resveratrol to its sulfate conjugate. 
 The proportions of absorbed intact trans-resveratrol and its glucuronide 
were estimated as f1 and (1-f1), respectively. The results showed that when the 
dose administered increased a lower fraction of trans-resveratrol remained 
unchanged (f1 = 0.420, 0.207 and 0.060 for the doses of 2, 10 and 20 mg·kg-1, 
respectively, and a body weight of 0.25 kg). By contrast, the relative fraction 
of glucuronide formed/absorbed from the intestine increased with the dose 
with values of 0.580, 0.793 and 0.94 for the doses of 2, 10 and 20 mg·kg-1 and 
a body weight of 0.25 kg, respectively. This suggested a non linear 
pharmacokinetic behaviour of trans-resveratrol, after p.o. administration from 
2 to 20 mg·kg-1.  
 It is known that trans-resveratrol and its conjugates accumulate 
significantly in the liver [18,28] and are further excreted into the bile, leading to 
enterohepatic recirculation [16,29]. The contribution of the biliar pathways to 
the elimination of the conjugated metabolites could not be captured by the 
present model although a light rebound was observed after 6 h of the i.v. 
administration, supporting the occurrence of the enterohepatic cycle. Previously, 
Marier et al. [29] have reported that the enterohepatic recirculation using a 
linked-rat model induced significant increase of plasma concentrations of 
resveratrol and its glucuronide in bile-recipient rats at 4 to 8 h. The population 
pharmacokinetic model built adequately described the plasmatic concentrations 
of trans-resveratrol and its major metabolites in the rat after i.v. and p.o. 
administrations, as it was verified with internal validation procedures [24]. Its 
predictive capacity was also evaluated using an external data set obtained after 
the i.v. administration of 15 mg·kg-1. The results showed a close agreement 
between the observed data and the predicted concentrations for the dose and 
administration route assayed, supporting the hypothesis of the robustness of the 
model. In summary, the population PK model built allowed to increase the 
knowledge to better understand the PK of this polyphenol but also may be 
applicable to many other compounds which have similar PK properties. In 
addition the model may also be useful for planning future PK–PD studies to 
establish the relative contribution of the conjugates to the overall efficacy.  
 In humans, Walle et al. showed that the majority of a dose of 25 mg 
administered p.o and i.v. was converted to trans-resveratrol sulfate within 30 min, 
and the serum peak concentrations of the parent compound were inferior to       
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22 nM [30]. Five metabolites were identified in urine, trans-resveratrol 
monosulphate, two isomeric monoglucuronides, dihydroresveratrol 
monosulphate and dihydroresveratrol monoglucuronide. The total sulfate and 
glucuronide conjugates accounted for approximately 37 and 19%, respectively 
of the metabolites in urine, and there were only trace amounts of free trans-
resveratrol [30]. A study of the pharmacokinetics of oral trans-resveratrol was 
performed after the administration of a single dose of 0.5, 1, 2.5 or 5 g in 
healthy volunteers [31]. An extensive metabolism after the oral administration 
was also reported since six metabolites were recovered from plasma and urine. 
Peak plasma concentration of trans-resveratrol was 2.4 µM at 1.5 hours after 
the oral administration of 5 g. Peak levels of two monoglucuronides and 
resveratrol 3-sulphate were 3- to 8-fold higher. The area under the plasma 
concentration curve values for trans-resveratrol-3-sulphate and trans-resveratrol 
monoglucuronides were 23 times greater than those of trans-resveratrol. 
Urinary excretion of trans-resveratrol and its metabolites was rapid, with  
77% of all urinary agent derived species excreted within 4 h after the lower 
dose (0.5 g).  
 
5. Toxicology 
 
 Several studies have evaluated the toxicity in mice and rats in short-term 
and subchronic administration of trans-resveratrol [32-34].  The repeated 
dosage of 20 mg/kg of trans-resveratrol during 28 days, which corresponds 
to 1000 times the amount that may be consumed by a person drinking one 
glass of red wine a day, did not induce any adverse effect [32]. Body 
weight, food and water consumption were not altered in rats exposed to 
trans-resveratrol, when compared to the control group. Hematologic and 
biochemical variables were not affected by the treatment. An increased 
relative brain weight and testicular weight normalized to body weight was 
observed in the group administered with trans-resveratrol whereas no 
histopatological changes in these organs were detected. In addition, trans-
resveratrol did not alter any vital organ weight or induce histopathologic 
changes [32].  
 The effect of higher doses was evaluated by the Crowell et al. [33]. 
Male and female Sprague-Dawley rats were administered by gavage 300, 
1000 and 3000 mg/kg of trans-resveratrol for 4 weeks. The results showed 
that no adverse effects were observed in male and female rats exposed to 
300 mg/kg. Minor effects were reported for the dose of 1000 mg/kg, such as 
reduced body weight in females and elevated leukocyte counts in males. The 
most remarkable adverse events took place at the highest dose of 3000 mg/kg, 
when a reduced body weight and food consumption, elevated kidney weight, 
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and increased incidence of kidney lesions were observed in male and female 
rats.  
 Those results were supported by the studies in which trans-resveratrol 
was incorporated in the diet at 50, 150 and 500 mg/kg during 28 days [34]. 
The dietary exposure did not induce any treatment-related effects on body 
weight clinical signs, hematological, clinical chemistry, histopatology or 
urinary parameters at any dose.  
 The reproductive toxicity of trans-resveratrol has been comprehensively 
evaluated. The administration of trans-resveratrol in the diet at 750 mg/kg 
during 90 days did not negatively affect sperm parameters or estrous cycle 
in the rat or any histopathological effect on reproductive organs [34]. trans-
Resveratrol has been administered at 0, 120, 300 and 750 mg/kg to pregnant 
rats, showing no adverse effects on the number of implantations, 
resorptions, live young, or pre- and post-implantation losses. In addition no 
negative findings were observed in the placental, litter and fetal weight; or 
incidence of major or minor fetal abnormalities at any of the doses tested 
[34].  
 In addition to the studies performed in rats, the toxicity has also been 
evaluated in p53 knockout mice, which is a model accepted for oncogenicity 
bioassays [35]. The animals were administered trans-resveratrol by gavage 
at 1000, 2000 or 4000 mg/kg during six months. No effects were observed 
on body weight, food consumption, or clinical signs in any dose group. 
However, a dose-related increase in liver weight and serum cholesterol 
concentrations were reported in both sexes. Histopathology identified the 
kidney (hydronephrosis) and urinary bladder (epithelial hyperplasia) as 
target tissues for resveratrol toxicity. The incidences of both benign and 
malignant tumors in mice exposed to trans-resveratrol were comparable to 
those in vehicle controls. When administered to p53 knockout mice at its 
maximum tolerated dose, trans-resveratrol demonstrates no evidence of 
oncogenicity [35]. This study performed in p53 knockout mice address a 
key regulatory requirement for the entry of resveratrol into clinical trials for 
cancer prevention. 
 A phase I study of the oral administration of single doses of trans-
resveratrol of 0.5, 1, 2.5 or 5 g conducted in 10 healthy volunteers per dose 
levels did not cause serious adverse events [31]. A safety profile of trans-
resveratrol was carried out in healthy volunteers that received 25, 50, 100 or 
150 mg, six times/day, for two days. This polyphenol was well tolerated and 
only mild adverse events were reported [36]. 
 Taken as a whole, the absence of symptoms and the normal appearance of 
the vital organs in rats and mice suggested that trans-resveratrol is barely 
toxic even under the conditions that have been described.  
Joana M. Planas et al.  112 
6. Health benefits of trans-resveratrol 
 
6.1. Colon cancer: In vivo and in vitro 
 
 Colorectal cancer is one of the leading causes of death in both men and 
women in Western countries, being usually lethal when diagnosed at later 
stages of progression [37]. Genetic predisposition as well as environmental 
aspects are thought to be involved in colon carcinogenesis, among which, 
dietary habits play a pivotal role. Mediterranean countries have lower rates of 
colorectal cancer compared with other Western countries [38]. It has been 
suggested that the environmental factors are mainly dietary and up to 80% of 
sporadic colorectal cancers are therefore potentially preventable [39].  
 trans-Resveratrol is gaining acceptance as a potential antitumor agent 
because of its multiple effects described in different experimental models of 
carcinogenesis [40,41]. This bioactive compound was shown to inhibit the 
growth of tumor cell lines derived from various human cancers, an effect 
that was associated with its ability to arrest cell cycle progression and to 
induce programmed cell death [40,41]. These antitumoral activities 
accompanied with the lack of harmful effects [32,34] makes trans-
resveratrol an attractive chemotherapy and chemopreventive drug for cancer 
treatment [40]. The low oral bioavailability established for trans-resveratrol 
both in experimental animals and humans, where the intestine has been 
pointed out as a bottleneck to its absorption, have promoted the large 
intestine as a potential target site thus favoring its potential 
chemopreventive activity in colon cancer.  
 The chemopreventive activity of trans-resveratrol against colon cancer 
was evaluated in vitro on the human colorectal carcinoma HT-29 by assessing 
its anti-proliferative and pro-apoptotic activities. Defects in the regulation of 
cell cycle progression constitute an important characteristic of transformed 
cells. Exposure of HT-29 cells to 10-300 µM of trans-resveratrol reduced cell 
growth, with half-maximal effects of around 80 μM [42]. Noteworthy, this 
polyphenol did not induce necrosis even at concentrations that caused full 
inhibition of cell growth. The antiproliferative activity of trans-resveratrol 
may be attributed to cell cycle arrest at G2 phase as was previously indicated 
for HT-29 cells [43] and Caco-2 cells [44,45].  
 Alterations in programmed cell death mechanisms play important roles in 
tumor pathogenesis, allowing neoplastic cells to survive beyond their 
normally intended lifespan, subverting the need for exogenous survival 
factors, providing protection from hypoxia and oxidative stress as tumor mass 
expands, and allowing time for accumulative genetic alterations that 
deregulate cell proliferation, interfere with differentiation, promote 
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angiogenesis, and increase cell motility and invasiveness during tumor 
progression [46]. Consequently, compounds that can eliminate aberrant cell 
clones by the induction of apoptosis may have a chemopreventive or even a 
therapeutic potential. The pro-apoptotic activities of trans-resveratrol were 
evaluated on HT-29 using a series of in vitro assays that allowed the 
evaluation of different stages of programmed cell death [42]. The activation of 
the effector caspase-3 was determined since it represents the converging point 
of different caspase-dependent apoptosis pathways [47]. trans-Resveratrol 
increased the activity of caspase-3 in a time- and a dose-dependent manner. 
The lowest concentration of trans-resveratrol that induced the activation of 
this protease was 100 μM with an incremented of 200% that of control cells, 
and the highest activation was achieved at 250 µM, with an increase of 7-fold 
[42]. Execution of apoptosis beyond activation of caspase-3 by trans-
resveratrol led to the characteristic hallmarks of programmed cell death, such 
as disintegration of the plasma membrane that was characterized by cell-
staining with Hoechst 33342 dye. Exposure of HT-29 cells with 150 μM of 
trans-resveratrol accumulated Hoechst dye over time, with an increase of 17.0 
± 2.7% and 33.0 ± 3.7% at 20 and 24 h over the control cells [42]. Full 
execution of apoptosis with increased fragmentation of DNA and chromatin 
condensation was evidenced by Hoechst 33258 staining. The presence of 
apoptotic bodies was evidenced in a 14.9 ± 1.4% of cells after 24 h of 
exposure to 150 µM of trans-resveratrol. 
 Several studies have indicated that reactive oxygen species (ROS) 
production in mitochondria play a role in the initiation and execution of 
apoptosis [48]. HT-29 cells exposed to 150 μM of trans-resveratrol showed 
markedly increased levels of superoxide anion radicals in mitochondria after 
4 hours of incubation. Consequently, the apoptotic effect of this polyphenol 
was mediated, in part, by the intrinsic pathway, through the production of 
superoxide anions in mitochondria prior to the initiation of the caspase 
pathway [42]. These results were in agreement with previous studies that 
pointed out superoxide anions as secondary messengers in apoptosis 
provoked by anticancer agents, such as paclitaxel and cisplatin [49,50]. In 
addition, trans-resveratrol was also reported to generate reactive oxygen 
species prior to the release of mitochondrial proteins to the cytosol, 
activation of effector caspase-3 and caspase-9, and induction of apoptosis in 
prostate cancer cells [51]. Reactive oxygen species production occurs in an 
early phase suggesting that the compound triggers a rapid release of 
cytochrome c from mitochondria into the cytosol that in turn activates 
procaspase-9 and the downstream effectors, including the pro-caspases -3, -
6, and -7, followed finally by the cleavage of proteins and DNA that 
characterize the final phase of apoptosis.  
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 Two principal pathways of apoptosis have been described, such as 
mitochondria-mediated intrinsic pathway and death receptor-induced extrinsic 
pathway [47]. However, it has been suggested that lysosomes and the 
endoplasmic reticulum also play important roles in programmed cell death 
[52]. In HT-29 cells, trans-resveratrol also triggers apoptosis through 
lysosome and demonstrates a hierarchy of the proteolytic pathways involved 
in its cytotoxic mechanism in which lysosomal cathepsin D acts upstream of 
caspase activation [53]. Furthermore, this polyphenol has been reported to 
promote apoptosis through the endosplasmic reticulum (ER) [54] and the 
induction of CHOP/GADD153 gene expression, which has been recognized as 
a proapoptosis gene [55].  
 The potential cancer chemopreventive activity of trans-resveratrol in vivo 
was evaluated in rats that received an intraperitoneal injection of 1,2-
dimethylhydrazine (DMH) [19]. The development of carcinogenesis in the 
DMH rat model takes place through a multistep process as it does in humans, 
and allowed the measurement of aberrant crypt foci (ACF) and mucin-
depleted foci (MDF) as valid early preneoplastic markers. ACF have been 
identified in humans at high risk and are widely used as a surrogate marker of 
colon cancer [56]. Prior to the performance of the study the experimental 
conditions were validated. Three subcutaneous injections of DMH (20 mg/kg, 
one week apart) followed by an observation period of four weeks proved to be 
appropriate for the screening of potentially chemopreventive agents [19]. 
trans-Resveratrol was administered at a dose 60 mg/kg since it was regarded 
as a potential nutraceutical and not in any case as an effect encountered after a 
long period of consumption of this polyphenol in the diet. trans-Resveratrol 
reduced the number of preneoplastic lesions, since ACF were inhibited by 
52%, and the total number of aberrant crypts (AC) by 50% [19]. In addition, 
MDF were described in carcinogen-treated rodents [57] and in humans at high 
risk of colon cancer [56]. MDF are characterized by harboring mutations that 
show Wnt signaling activation like in colon tumors, suggesting that these 
lesions are precancerous [56]. trans-Resveratrol oral administration for 49 
days reduced the number of MDF by 50%, thus remarking the protecting 
activity exerted by this compound in the colon mucosa. Given that trans-
resveratrol was administered one week prior to the first exposure to DMH, the 
results demonstrated that trans-resveratrol acts as an efficient agent inhibiting 
cancer initiation [19]. 
 The potential cancer chemopreventive activity of trans-resveratrol in vivo 
was examined previously in long-term studies [45,58-61]. The effect of trans-
resveratrol on azoxymethane-induced colon carcinogenesis was assessed in 
F344 rats. This phytochemical was administered in drinking water at a dose of 
200 µg/kg for 100 day, beginning 10 days before administration of the 
Resveratrol: A polyphenol with multiple effects 115 
carcinogen [59]. trans-Resveratrol reduced the growth of colorectal ACF 
modulating the expression of bax and p21, both involved in the regulation of 
cell proliferation and apoptosis [59]. Sengottuvelan et al. also assessed the 
anticarcinogenic activity of 8 mg/kg of trans-resveratrol in a model of colon 
carcinogenesis induced by DMH, but these were long term experiments that 
lasted 30 weeks [58,60]. Their results showed that in rats, trans-resveratrol 
markedly reduced the number of 1,2-dimethylhydrazine–induced aberrant 
crypt foci and incidence and size of tumors, possibly through the modulation 
of antioxidant defense status and activities of carcinogen-detoxifying enzymes 
[58,60]. In ApcMin mice, which are a model of human familial adenomatous 
polyposis, trans-resveratrol administered in drinking water at a dose of          
15 mg/kg for 7 weeks prevented the formation of colon tumors and reduced 
the formation of small intestinal tumor by 70% by down-regulating genes that 
are directly involved in cell cycle progression such as cyclin D1, D2 and DP-1, 
and in the inhibition of the carcinogenic process and tumor expansion [45]. In 
the same animal model, trans-resveratrol (0.2% in the diet) decreased the 
number of adenomas, which was associated with inhibition of COX enzymes 
and interference with prostaglandin E2 (PGE2) generation [62]. In contrast, 
trans-resveratrol administered in the diet at 0, 4, 20, or 90 mg/kg body weight 
for 7 weeks did not affect intestinal tumorigenesis or COX-2 expression in 
ApcMin/+ mice [61]. 
 
6.2. Spermatogenesis  
 
 The mammalian testis fulfills two main functions, namely, the synthesis 
of steroid hormones and the production of spermatozoa, which are controlled 
by gonadotrophins and testosterone together with locally produced factors 
[63]. The repeated oral administration of 20 mg/kg of trans-resveratrol during 
90 days enhanced both functions. Sperm counts were significantly greater in 
the resveratrol treated rats (24.8 ± 3.30·107) than in the control group (14.1 ± 
0.80·107) [64]. The experimental data showed that the repeated oral 
administration of trans-resveratrol induced a 71% decrease in the mean 
diameter of the seminiferous tubules with a 100% increase in the testicular 
tubular density. Taken together, these changes result in an overall increase in 
the size of the spermatogenic tissue. Therefore, this enlargement would be in 
the basis of the observed increase of sperm production. It is noteworthy that 
sperm collected from the epididymis showed a correct maturation since the 
morphological examination evidenced the same percentage of abnormalities 
between groups. As a conclusion, these results suggest that the trans-
resveratrol-induced increment in total sperm content would be due more to an 
enlargement in the overall tissue that produces mature sperm cells than to an 
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increase in the rhythm of sperm production, which would remain unchanged 
with respect to the control animals [64]. 
 Spermatogenesis depends on the delicate balance that constitutes the 
hypothalamic-pituitary-gonadal axis. The endocrine regulation of this axis in 
the male is intricate with a role for estradiol and testosterone, making obvious 
the complexity of the steroid-feedback mechanisms [65]. The sites for these 
feedback effects include cells in the hypothalamus, that are in close proximity 
to gonadotrophin-releasing hormone (GnRH) neurons, and gonadotrophins in 
the pituitary, that may respond directly to androgens due to the expression of 
the androgen receptor (AR), whereas the presence of aromatase and the 
estrogen receptor (ER) allows the conversion of androgens into estrogens, and 
the subsequent activation of ER signaling pathways [65]. The oral 
administration of 20 mg/kg of trans-resveratrol for 90 days also exerted a 
stimulatory effect on the secretion of gonadotrophins that are the major 
endocrine regulators of spermatogenesis [64]. The concentration of FSH, 
which acts within the tubules to stimulate spermatogenesis, and LH, that 
signals the production of testosterone in Leydig cells were both elevated in the 
resveratrol group with respect to the control rats. Testosterone, which is 
essential for promoting spermatogenesis, was also enhanced. These results 
seem to indicate that the effect of trans-resveratrol on sperm count was caused 
by the hypophisary stimulation of the testicular function.  
 A possible explanation to the described effect could be that trans-
resveratrol binds ER as a mixed weak agonist/antagonist, without estrogenic 
properties [40]. The fact that trans-resveratrol lacks estrogenic activity 
could be confirmed by the absence of deleterious effects on testes, in 
opposition to the toxicity described for diethylstilbestrol (DES) [66]. Rats 
treated with DES, which is a structural analog of trans-resveratrol, and a 
potent estrogen agonist, showed reduction in testicular weight, impaired 
seminiferous tubular morphology and reduced testosterone concentration 
[66]. The distinct activity shown by two structurally similar compounds can 
be explained by subtle differences in both molecules. Compared to trans-
resveratrol, DES lacks the 3-OH and 5-OH groups, but on the contrary 
possesses a 4-OH group and two additional ethyl groups. These features 
provide differential binding characteristics to ER [67]. DES holds similar 
affinity as estradiol to ER acting as a full potent agonist, thus accounting for 
the harmful effects described.  
 In addition, the daily oral administration of 20 mg/kg of trans-resveratrol 
for 90 days did not induce any differences in body weight, food and water 
consumption in the treated group with respect to the control rats [64]. Given 
that growth inhibition is a sensitive indicator of estrogenic effects [68], this 
lack of reduction in body weight in the treated rats substantiates that              
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trans-resveratrol does not act as an estrogen agonist, in agreement with other 
in vivo studies [69,70].  
 Consequently, trans-resveratrol could interact with ER, thus increasing 
the secretion of gonadotrophins which leads in turn to an increment in 
testosterone and sperm output. Furthermore, the effects described above could 
have been reinforced through androgen antagonism, since trans-resveratrol 
has also been revealed to antagonize androgen action in prostate cancer cells 
by inhibiting AR activity as well as by suppressing AR expression [71,72]. 
Besides the effect of trans-resveratrol on the hypothalamic-pituitary-gonadal 
axis, its antioxidant and anti-inflammatory activity also warrants attention. 
Taken as a whole, these actions could also account for the increase on sperm 
output observed in healthy rats. In Western society, infertility is a growing 
problem, the causes are diverse and considerable effort is being made to offer 
effective therapy. In the search for solutions, in the case of male infertility, 
antioxidants, anti-inflammatories, androgens and antiestrogens are among the 
treatments used. However, truly effective treatment has still to be found [73]. 
Therefore, the effect of trans-resveratrol on spermatogenesis merits further 
research since this compound may be useful in the treatment of male infertility. 
 
7. Conclusions 
 
 In the present review we summarize the current evidence about the role of 
ABC transporters both in the absorption and distribution of trans-resveratrol 
that contribute to the low bioavailability of this compound. Moreover, we 
provide evidence that trans-resveratrol, as a pharmacological agent, has an 
important effect in the prevention of colon cancer as well as in masculine 
infertility. The wide spectrum of this compound may reflect its simultaneous 
action on multiple molecular targets.  
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